

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

March 28, 2024

Kiran Asarpota Chief Operating Officer ASLAN Pharmaceuticals Ltd 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190

> Re: ASLAN Pharmaceuticals Ltd Registration Statement on Form F-3 Filed March 25, 2024 File No. 333-278217

Dear Kiran Asarpota:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Carlos Ramirez